Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Lobular × Goserelin × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 50 Breast Neoplasms 37 Neoplasms 4 Salivary Gland Neoplasms 3 Prostate Adenocarcinoma 2 Triple Negative Breast Neoplasms 1 Recurrence 1 PSA Level Greater Than Two 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphatic Metastasis 1 Inflammatory Breast Neoplasms 1 Hormone-sensitive Metastatic Breast Cancer 1 Hormone Sensitive Prostate Cancer 1 Hodgkin Disease 1 Hereditary Sensory and Autonomic Neuropathies 1 HER2-positive Breast Cancer 1 HER2 Negative Breast Cancer 1 Fallopian Tube Neoplasms 1 Castrate Sensitive Prostate Cancer 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Lobular 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms, Male 1 Anatomic Stage I Breast Cancer AJCC v8 1 Advanced Breast Cancer 1

Interventions

Trastuzumab 2 Letrozole 2 Cyclophosphamide 2 Carboplatin 2 repotrectinib 1 proto-oncogene protein c-fes-fps 1 palbociclib 1 neratinib 1 entrectinib 1 Vinorelbine 1 Thiotepa 1 Tamoxifen 1 Sugars 1 Radiotherapy 1 Positron Emission Tomography Computed Tomography 1 Paclitaxel 1 Neoadjuvant Therapy 1 Naltrexone 1 Melphalan 1 Mastectomy, Segmental 1 Magnetic Resonance Spectroscopy 1 Liquid Biopsy 1 High-Energy Shock Waves 1 Goserelin 1 Fulvestrant 1 Fluorine-18 1 Epirubicin 1 Docetaxel 1 Chemotherapy, Adjuvant 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04551495 2024-12-04

ROSALINE

Jules Bordet Institute

Phase 2 Active not recruiting

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡